Information  X 
Enter a valid email address

Summit Corporation (SUMM)

  Print      Mail a friend

Friday 12 October, 2007

Summit Corporation

Notice of Results

Summit Corporation PLC
12 October 2007

Summit Corporation plc
('Summit' or 'the Company')



NOTICE OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 JULY 2007



Oxford, UK, 12 October 2007 - Summit Corporation plc (AIM: SUMM) will announce
its interim results for the six months ended 31 July 2007 on Tuesday, 30 October
2007.  A presentation to analysts will be held on this day at 09.30hrs at the
offices of Citigate Dewe Rogerson, 3 London Wall Buildings, London Wall, London
EC2M 5SY.



                                    - ENDS -

For more information, please contact:

Summit plc
Steven Lee, PhD, Chief Executive Officer                Tel: +44 (0)1235 443951
Darren Millington, ACMA, Chief Financial Officer
Richard Pye, PhD, Investor Relations


Citigate Dewe Rogerson
Mark Swallow / David Dible / Yvonne Alexander           Tel: +44 (0)207 638 9571


Evolution Securities
Tim Worlledge / Bobbie Hilliam / Neil Elliot            Tel: +44 (0)207 071 4300



About Summit plc

Summit plc is a leading UK biotechnology company that discovers and develops
proprietary new drugs. The Company's internal drug development programmes are
underpinned by its advanced carbohydrate chemistry and drug screening (chemical
genomics) technology platforms, which it also provides on a collaborative or
fee-for-service basis to the pharmaceutical industry.

Summit plc has a broad range of drug discovery programmes in the clinical,
pre-clinical and discovery stages of development, which target serious diseases
with a high unmet medical need. These therapeutic areas include neuro-disorders
(neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases,
oncology and regenerative medicines.

Summit plc's in-house drug development capabilities combine world-class
expertise in both carbohydrate chemistry with high-volume, high-content
screening using its proprietary zebrafish and fruitfly technologies (chemical
genomics). These whole organism screens have the potential to dramatically
decrease the time and cost of drug discovery and development by delivering data
that are highly predictive of the efficacy and toxicity of potential drug
compounds in humans.

The company listed on the AIM market of the London Stock Exchange in October
2004 - symbol: SUMM

Further information about the company is available at www.summitplc.com



This document contains 'forward-looking statements' within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as 'anticipates', 'intends', 'plans',
'seeks', 'believes', 'estimates', 'expects' and similar references to future
periods, or by the inclusion of forecasts or projections.

Forward-looking statements are based on the Company's current expectations and
assumptions regarding our business, the economy and other future conditions.
Because forward-looking statements relate to the future, by their nature, they
are subject to inherent uncertainties, risks and changes in circumstances that
are difficult to predict. The Company's actual results may differ materially
from those contemplated by the forward-looking statements. The Company cautions
you therefore that you should not rely on any of these forward-looking
statements as statements of historical fact or as guarantees or assurances of
future performance. Important factors that could cause actual results to differ
materially from those in the forward-looking statements and regional, national,
global political, economic, business, competitive, market and regulatory
conditions.


                      This information is provided by RNS
            The company news service from the London Stock Exchange